Acrivon Therapeutics Inc’s recent filing unveils that its 10% Owner PERCEPTIVE ADVISORS LLC acquired Company’s shares for reported $20.0 million on Apr 11 ’24. In the deal valued at $8.50 per share,2,353,000 shares were bought. As a result of this transaction, PERCEPTIVE ADVISORS LLC now holds 5,360,858 shares worth roughly $50.77 million.
Then, Chione Ltd sold 16 shares, generating $207 in total proceeds. Upon selling the shares at $12.93, the 10% Owner now owns 3,848,632 shares.
Before that, Chione Ltd sold 2,056 shares. Acrivon Therapeutics Inc shares valued at $24,960 were divested by the 10% Owner at a price of $12.14 per share. As a result of the transaction, Chione Ltd now holds 3,848,648 shares, worth roughly $36.45 million.
JMP Securities initiated its Acrivon Therapeutics Inc [ACRV] rating to a Mkt outperform in a research note published on March 01, 2024; the price target was $14. Maxim Group began covering ACRV with “Buy” recommendation on October 05, 2023. Oppenheimer started covering the stock on June 02, 2023. It rated ACRV as “an Outperform”.
Price Performance Review of ACRV
On Tuesday, Acrivon Therapeutics Inc [NASDAQ:ACRV] saw its stock fall -1.46% to $9.47. Over the last five days, the stock has lost -1.56%. Acrivon Therapeutics Inc shares have risen nearly 92.48% since the year began. Nevertheless, the stocks have risen 13.01% over the past one year. While a 52-week high of $14.30 was reached on 04/09/24, a 52-week low of $3.19 was recorded on 02/13/24. SMA at 50 days reached $5.64, while 200 days put it at $7.27. A total of 0.2 million shares were traded, compared to the trading of 0.39 million shares in the previous session.
Levels Of Support And Resistance For ACRV Stock
The 24-hour chart illustrates a support level at 9.15, which if violated will result in even more drops to 8.82. On the upside, there is a resistance level at 9.80. A further resistance level may holdings at 10.12. The Relative Strength Index (RSI) on the 14-day chart is 65.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.71, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 39.19%. Stochastics %K at 64.35% indicates the stock is a holding.
The most recent change occurred on May 08, 2023 when BMO Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $25 price target.
